The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation

Science - United States
doi 10.1126/science.1201662
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for the Advancement of Science (AAAS)

Related search

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML

Cell Reports
BiochemistryGeneticsMolecular Biology
2016English

Improved Species-Specific Lysine Acetylation Site Prediction Based on a Large Variety of Features Set

PLoS ONE
Multidisciplinary
2016English

LAceP: Lysine Acetylation Site Prediction Using Logistic Regression Classifiers

PLoS ONE
Multidisciplinary
2014English

Detection of DNA Rearrangements in the AML1 and ETO Loci and of an AML1/ETO Fusion mRNA in Patients With T(8;21) Acute Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
1993English

NHR4 Domain Mutations of ETO Are Probably Very Infrequent in AML1–ETO Positive Myeloid Leukemia Cells

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Epigenetic Consequences of AML1-ETO Action at the Human C-FMS Locus

EMBO Journal
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
2003English

The Effect of Site-Specific Acetylation Based Tau Mutations on Tau-Microtubule Associations

Biophysical Journal
Biophysics
2019English

ETO, but Not Leukemogenic Fusion Protein AML1/ETO, Augments RBP-J /SHARP-Mediated Repression of Notch Target Genes

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2008English

Histone 3 Lysine 9 Acetylation Is a Biomarker of the Effects of Culture on Zygotes

Reproduction
Cell BiologyGynecologyEndocrinologyReproductive MedicineObstetricsEmbryology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy